Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. Issue 10 (October 2015)

• Record Type: Journal Article
• Authors: Gautschi, Oliver; Milia, Julie; Cabarrou, Bastien; Bluthgen, Marie-Virginia; Besse, Benjamin; Smit, Egbert F; Wolf, Juergen; Peters, Solange; Früh, Martin; Koeberle, Dieter; Oulkhouir, Youssouf; Schuler, Martin; Curioni-Fontecedro, Alessandra; Huret, Benjamin; Kerjouan, Mallorie; Michels, Sebastian; Pall, Georg; Rothschild, Sacha; Schmid-Bindert, Gerald; Scheffler, Matthias; Veillon, Rémi; Wannesson, Luciano; Diebold, Joachim; Zalcman, Gérard; Filleron, Thomas; Mazières, Julien
• Is Part Of: Journal of thoracic oncology. Volume 10:Issue 10(2015)
• Publication Date: 2015-10
• Subjects: Lung cancer -- Targeted therapy -- BRAF -- Vemurafenib -- Dabrafenib; Chest -- Cancer -- Periodicals; Thoracic Neoplasms -- Periodicals; 616.99494005
• DOI: 10.1097/JTO.0000000000000625
• Languages: English
• ISSNs: 1556-0864

Abstract

Abstract : Introduction: Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib, dabrafenib, and sorafenib as BRAF inhibitors are currently tested in clinical trials, but access for patients is limited. The aim of this study was to document the clinical course of patients treated outside of clinical trials. Methods: We conducted a retrospective multicenter cohort study in Europe of patients with advanced BRAF-mutant lung cancer treated with known BRAF inhibitors. Data were anonymized and centrally assessed for age, gender, smoking, histology, stage, local molecular diagnostic results, systemic therapies, and survival. Best response was assessed locally by RECIST1.1. Results: We documented 35 patients treated in 17 centers with vemurafenib, dabrafenib, or sorafenib. Median age was 63 years (range 42–85); gender was balanced; 14 (40%) were never smokers; all (100%) had adenocarcinoma; 29 (83%) had V600E; 6 (17%) had other mutations; one of them had a concomitant KRAS mutation. Thirty (86%) patients had chemotherapy in the first line. Overall survival with first-line therapy was 25.3 months for V600E and 11.8 months for non-V600E. Thirty-one patients received one BRAF inhibitor, and four received a second inhibitor. Overall response rate with BRAF therapy was 53%, and disease control rate was 85%. Median progression-free survival with BRAF therapy was 5.0 months, and overall survival was 10.8 months. Conclusions: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.